Methylergonovine Powder CAS 113-42-8

Methylergonovine powder is a compound that is an alkylation product of LSA (Lysergic acid amide) derivative. Is a solid substance that usually occurs as a powder or crystals. It can be white, yellowish or brownish in color and has a certain smell. Poor solubility in water, difficult to dissolve completely. In acidic or alkaline solutions, it has poor stability and is easy to decompose, and has high solubility in ethanol and methanol. It is a drug with a structure similar to lysergic acid and is mainly used to treat gynecological diseases such as mastitis, uterine cramping and bleeding. Because of its remarkable therapeutic effect, it has been widely used in medical practice.

Methylergonovine powder, or MEV for short, is a drug commonly used to treat symptoms such as postpartum hemorrhage, miscarriage, induced abortion, and menstrual disorders. It is a synthetic drug derived from ergot alkaloids.

Postpartum hemorrhage refers to excessive bleeding after childbirth, which can lead to serious complications such as anemia and even shock in the parturient. Methylergonovine works by binding to specific receptors in the uterine smooth muscle, causing the muscle to contract. This contraction helps to compress blood vessels in the uterine wall, reducing blood flow and controlling bleeding.

• Bleeding After Surgery: It can help control bleeding in surgical procedures involving the uterus or related tissues.
• Bleeding After Abortion: By stimulating uterine contractions, it aids in the expulsion of residual tissue and reduces bleeding after induced abortions.
• Bleeding After Hysterectomy: In some cases, it may be used to control bleeding post-hysterectomy, although this use may vary depending on the specific surgical procedure and patient condition.

Methylergonovine can promote uterine contraction and tension, reduce bleeding during abortion, and also prevent uterine remnants and reduce endometriosis. However, for the treatment of miscarriage, which is not one of the conventional treatments and generally needs to be used under the advice of a doctor.

Methylergonovine is also used to treat bleeding and secondary symptoms after induced abortion. It can help the uterus return to normal contraction and tension, relieve symptoms, and also help avoid uterine residues.

Methylergonovine can also treat complex menstrual disorders such as dysmenorrhea, menorrhagia, and irregular periods. It can regulate uterine contraction and tension, promote uterine endocrine function, relieve symptoms and restore normal menstrual flow.

Methylergonovine has a blood vessel contraction and uterine contraction effect, and it is also an effective, selective 5-HT receptor antagonist. However, when treating Raynaud's phenomenon, its main pharmacological effect is not to directly dilate blood vessels, but to indirectly affect the comfort function of vascular smooth muscle by regulating 5-HT receptor activity.
By regulating the comfort function of vascular smooth muscles, it can increase blood flow to the across, thereby alleviating the symptoms of Rayno's phenomenon, such as skin color changes, pain, etc.

Methylergonovine acts directly on the smoothing muscle of the uterine, causing uterine contraction. This contraction can oppress the blood vessels in the uterus, reduce bleeding, and help the recovery of cervix and uterus.

In conclusion, Methylergonovine is a commonly used drug widely used in the treatment of many obstetric and gynecological diseases. However, the use requires caution and must be used under the advice and supervision of a doctor to avoid adverse reactions and side effects.

Methylergonovine powder is a synthetic drug, a semi-synthetic derivative. It is a semi-synthetic plant ingredient, originally extracted from lysergic acid and now mainly prepared by chemical synthesis.

• Preparation of 8-bromo-1-methyl-6-methylergoline. 5-methyl-8-bromo-1H-indole-3-acetic acid and 1-methyl acetate were reacted for more than 4 hours, and the reaction solution was added to acetone. For the protection of the 6-position of the produced 6-bromo-8-methylergolin, where an acetyl group is added, a polystyrene resin having an affinity for acetone was used. After the reaction, the reactant was purified by adsorption-type silica gel column chromatography to obtain 8-bromo-1-methyl-6-methylergoline.
• Preparation of Methylergonovine. 8-Bromo-1-methyl-6-methylergoline was reacted with cyanobenzoate. Adding dibenzoyl chloride (DPC) to the reaction can form a cyanobenzoate intermediate. This intermediate is then hydrogenated (using aluminum trihydride) and esterified (using dipropyl malonate) to give Methylergonovine. Finally, Methylergonovine is purified by methods such as crystallization or column chromatography.

Methylergonovine is more stable than ergotamine and can be stored at room temperature for a long time. It is not easily affected by air, water and light, and is not affected by slight acids or alkalis. The ultraviolet absorption spectrum of it has a certain absorption peak at 220nm, and the absorption intensity is the strongest at this time. Which can be hydrolyzed under alkaline conditions, and its product is ergoline. Under physiological conditions, the hydrolysis rate of Methylergonovine is relatively slow, so it has a longer duration of drug effect. And has a strong electron cloud and strong nucleophilicity, and can undergo nucleophilic addition reactions with other chemical substances. For example, it can undergo nucleophilic addition reactions with phenols to produce phenol-like products. There may be residual organic solvents in the preparation of Methylergonovine, such as ethanol, n-butanol, etc. These organic solvents may affect the quality of Methylergonovine powder, so proper purification and detection must be carried out.

Hot Tags: methylergonovine powder cas 113-42-8, suppliers, manufacturers, factory, wholesale, buy, price, bulk, for sale, Medetomidine HCl, levamisole hydrochloride powder, tetramisole hydrochloride powder, Medetomidine hydrochloride, raloxifene powder, 1 3 Dimethylpentylamine